Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 123

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 123
---
 or harm our reputation, and we may be unable to regain those customers in the future. Although we possess insurance for damage to our property and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, if at all. Our operations currently do not use third party laboratories to process samples for our tests and services. If we were to rely on a third party to process some of our tests in certain markets, we would use only facilities with certain established accreditations. For example, in the US we would seek state licensure and CLIA accreditation, and for tests provided internationally, ISO 15189 accreditation. We cannot assure you that we would be able to find CLIA or ISO 15189 -certifiedfacility willing to comply with the required procedures, that this laboratory would be willing to perform the tests for us on commercially reasonable terms, or that it would be able to meet our quality or regulatory standards. In order to set up a new wet -laboutside of our existing facilities, we would have to spend considerable time and money securing adequate space, constructing the facility, recruiting and training employees, and establishing the additional operational and administrative infrastructure necessary to support additional facilities. We may not be able, or it may take considerable time, to replicate our testing processes or results in a new facility. Additionally, any new clinical reference laboratory facility opened by us would be subject to certification under the European Molecular Genetics Quality Network (“EMQN”) and/or the College of American Pathologists (“CAP”), which could take a significant amount of time and result in delays in our ability to resume operations. These challenges could be amplified if we or our joint ventures or other commercial partners seek to procure and maintain laboratory space in the United States and Latin American region as we pursue international expansion. In addition, Mexico is a seismic region. The inability to open the planned facility in Mexico, delays in opening such facility due to logistical complications or natural disasters, or failure to obtain required permits, licenses, or certifications, could result in increased costs and prevent us from realizing the intended benefits of the new facility. 36 We are unable to predict the extent to which potential pandemics or outbreaks of communicable diseases will adversely impact our business operations and financial results. Our operations, business and financial condition could be materially and adversely affected by epidemics and other outbreaks of communicable diseases, including the COVID -19pandemic, and by the economic and operational disruptions caused by the attempts of governmental